Medical Innovation Exchange

Moderna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data

https://www.fiercebiotech.com/biotech/moderna-dinged-lukewarm-flu-data-waits-efficacy-readout-charting-regulatory-course

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!